No record found
No record found
* Returns not adjusted for payouts
Company Profile
GlaxoSmithKline Pakistan Limited is incorporated in Pakistan as a limited liability company. It is engaged in manufacturing and marketing of research based ethical specialties and pharmaceutical products. The Company is a subsidiary of S.R. One International B.V., incorporated in Netherlands, whereas its ultimate parent company is GlaxoSmithKline plc, UK (GSK plc).
Erum Shakir Rahim | CEO |
Lai Kuen Goh | Chairperson |
Hina Mir | Company Secretary |
CDC Share Registrar Services Limited CDC House, 99 - B, Block - B S.M.C.H.S., Main Shahra-e-Faisal Karachi
Yousuf Adil, Chartered Accountants
December
Equity Profile
Announcements
Date | Title | Document |
---|---|---|
Oct 29, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited TRANSMISSION OF QUARTERLY ACCOUNTS FOR THE PERIOD ENDED SEP. 30, 2024 | |
Oct 28, 2024 | Financial Results for the nine months ended September 30,2024 | View PDF |
Oct 28, 2024 | Financial results for the nine months ended September 20, 2024 REVOKED | View PDF |
Aug 29, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited Transmission of Half yearly Report for the Period Ended June 30, 2024 | |
Aug 23, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited Financial Results for the Half Year Ended June 30 2024 | |
Jul 23, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited Other Than Financial Results | |
Apr 30, 2024 | Transmission of Quarterly Account for the Period Ended March 31, 2024 | View PDF |
Apr 26, 2024 | Financial Results for the quarter ended March 31,2024 | View PDF |
Apr 3, 2024 | Transmission of Annual Report for the year ended December 31, 2023 | View PDF |
Mar 26, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023 - GLAXO |
Date | Title | Document |
---|---|---|
Oct 21, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited Board Meeting | |
Aug 16, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited Board Meeting | |
Jul 30, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited GSK Board Meeting Result other than Financial Results July 30 2024 | |
Apr 24, 2024 | Certified True Copy of Resolution passed by the Shareholders in the Annual General Meeting held on April 24, 2024 | View PDF |
Apr 19, 2024 | Board Meeting for the quarter ended March 31, 2024 | View PDF |
Apr 3, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited - Notice of Annual General Meeting | |
Mar 19, 2024 | Board of Directors Meeting - 4th Quarter 2023 on 26 March 2024 | View PDF |
Oct 17, 2023 | Board Of Directors Meeting | View PDF |
Aug 15, 2023 | Board Meeting | View PDF |
May 24, 2023 | Certified True Copy of Resolution passed by the Shareholders in the Annual General Meeting held on May 24, 2023 | View PDF |
Date | Title | Document |
---|---|---|
Nov 18, 2024 | Material Information | View PDF |
Nov 11, 2024 | Presentation of Corporate Briefing Session 2024 | View PDF |
Nov 8, 2024 | Notice of Corporate Briefing Session - 2024 | View PDF |
Oct 4, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited UNUSUAL MOVEMENT IN THE PRICE OF SHARES OF GlaxoSmithKline Pakistan Limited | |
Jun 11, 2024 | Appointment of Company Secretary | View PDF |
Jun 10, 2024 | Resignation of Company Secretary | View PDF |
May 20, 2024 | Unusual Movement in the price of shares | View PDF |
Apr 23, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited Material Information | |
Dec 13, 2023 | Presentation of Corporate Briefing Session - 2023 | View PDF |
Dec 11, 2023 | GLAXO | GlaxoSmithKline Pakistan Limited- CORPORATE BRIEFING SESSION - 2023 |
Financials
All numbers in thousands (000's) except EPS
2023 | 2022 | 2021 | 2020 | |
---|---|---|---|---|
Sales | 49,661,277 | 41,841,585 | 36,660,772 | 35,090,112 |
Profit after Taxation | 533,953 | 2,462,892 | 5,354,409 | 3,375,240 |
EPS | 1.68 | 7.73 | 16.81 | 10.60 |
Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | |
---|---|---|---|---|
Sales | 14,730,940 | 13,254,797 | 15,616,126 | 13,770,544 |
Profit after Taxation | 1,927,134 | 1,088,869 | 565,281 | (69,790) |
EPS | 6.05 | 3.42 | 1.78 | (0.22) |
Ratios
2023 | 2022 | 2021 | 2020 | |
---|---|---|---|---|
Gross Profit Margin (%) | 7.05 | 17.40 | 26.56 | 21.47 |
Net Profit Margin (%) | 1.08 | 5.89 | 14.61 | 9.62 |
EPS Growth (%) | (78.27) | (54.02) | 58.58 | 10.99 |
PEG | (0.63) | (0.21) | 0.14 | 1.65 |
Payouts
Date | Financial Results | Details | Book Closure |
---|---|---|---|
February 28, 2022 11:32 AM | 31/12/2021(YR) | 70%(F) (D) | 19/04/2022 - 25/04/2022 |
March 10, 2021 3:45 PM | 31/12/2020(YR) | 65%(F) (D) | 21/04/2021 - 27/04/2021 |
March 11, 2020 5:58 PM | 31/12/2019(YR) | 60%(F) (D) | 15/05/2020 - 21/05/2020 |
March 4, 2019 4:53 PM | 31/12/2018(YR) | 70%(F) (D) | 18/04/2019 - 24/04/2019 |
February 27, 2018 3:59 PM | 31/12/2017(YR) | 40% (D) | 18/04/2018 - 24/04/2018 |
October 26, 2017 5:47 PM | 30/09/2017(IIIQ) | 30% (D) | 10/11/2017 - 17/11/2017 |
March 8, 2017 4:03 PM | 31/12/2016(YR) | 60% (D) | 18/04/2017 - 24/04/2017 |
March 30, 2016 3:13 PM | 31/12/2015(YR) | 40% (D) | 20/04/2016 - 27/04/2016 |
February 25, 2015 3:51 PM | 31/12/2014(YR) | 50% (D) | 16/04/2015 - 23/04/2015 |
February 7, 2014 3:24 PM | 31/12/2013(YR) | 35% (D) - 10% (B) | 21/04/2014 - 28/04/2014 |